Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.42 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | CTSL | P07711 | 3/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862892 | 0.88 | CTSK (0.49) | CTSKCTSSCTSLCTSBHTR2C | |
| SCHEMBL21429034 | 0.84 | DPP7 (0.35) | CTSKCTSSCTSBCTSCREN | |
| SCHEMBL22928945 | 0.84 | DPP7 (0.35) | CTSKCTSSCTSBCTSCREN | |
| SCHEMBL6858875 | 0.79 | CTSC (0.53) | CTSKHTR2CHTR2BCTSCREN | |
| SCHEMBL6858874 | 0.79 | CTSC (0.53) | CTSKHTR2CHTR2BCTSCREN | |
| SCHEMBL7015789 | 0.79 | CTSC (0.53) | CTSKHTR2CHTR2BCTSCREN | |
| SCHEMBL21430273 | 0.79 | PTPN1 (0.49) | CTSKCTSSCTSLCTSB | |
| SCHEMBL30487486 | 0.74 | HTR2C (0.51) | CTSKCTSSCTSLCTSBHTR2C | |
| SCHEMBL29630524 | 0.74 | REN (0.54) | CTSCREN | |
| SCHEMBL8773302 | 0.73 | HTR2C (0.63) | HTR2CHTR2BCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
| US-20210024579-A1 | MACROCYCLIZATION OF PEPTIDOMIMETICS | UNIVERSITY OF WARWICK (GB) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024579-A1 | MACROCYCLIZATION OF PEPTIDOMIMETICS | NGLY1, MAX, VIP | CTSK 1350/4885CTSS 1471/4885CTSL 769/4885 |
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | CTSK 528/4885CTSS 666/4885CTSL 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.